NEWWeight Loss
Retatrutide (Triple Agonist GIP/GLP-1/Glucagon)
Triple-action incretin agonist — cutting-edge metabolic research
Select Size
Most researchers order 2+ vials per protocol
For research use only. Not for human consumption.
Overview
Retatrutide is a novel triple-hormone receptor agonist targeting the GIP, GLP-1, and glucagon receptors simultaneously. This unique pharmacological profile allows investigation of synergistic metabolic effects across three distinct incretin and glucagon signaling pathways. The glucagon receptor component adds a thermogenic and lipolytic dimension beyond traditional dual agonists. Retatrutide represents the latest advancement in multi-receptor metabolic peptide research.
Specifications
| Form | Lyophilized Powder |
| Purity | ≥99% (HPLC Verified) |
| Storage | -20°C (Freeze Dried) |
| Molecular Weight | 4604.17 g/mol |
Frequently Asked Questions
Retatrutide is a novel triple-hormone receptor agonist that targets GIP, GLP-1, and glucagon receptors simultaneously. The addition of the glucagon receptor component provides a thermogenic and lipolytic dimension beyond traditional single or dual agonists, representing the latest advancement in multi-receptor metabolic peptide research.
Unlike single-target compounds (Semaglutide / GLP-1 only) or dual-target compounds (Tirzepatide / GIP + GLP-1), Retatrutide activates three distinct receptor systems. This triple-agonist profile allows investigation of synergistic effects across incretin and glucagon signaling pathways in a single compound.
Our Retatrutide is verified at ≥99% purity via third-party HPLC analysis. Each batch ships with a Certificate of Analysis documenting purity, identity, and residual solvent levels.
Complete Your Stack
Frequently purchased together with Retatrutide
